What is Yupelri 175 mcg/3 mL solution for nebulization?
Yupelri (revefenacin) 175 mcg/3 mL solution for nebulization is a medication prescribed to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is administered as a once-daily maintenance treatment for COPD [2].
How does Yupelri work for COPD?
Yupelri is a long-acting muscarinic antagonist (LAMA). It works by relaxing the muscles around the airways in the lungs, which helps to open them up and make breathing easier [1][2]. This mechanism of action aims to reduce symptoms like shortness of breath, coughing, and wheezing associated with COPD [1].
When does Yupelri's patent protection end?
The patent expiry for Yupelri is a key factor in the potential for generic competition. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Yupelri. Information regarding specific patent expiration dates can be found on their platform [1].
Can biosimilars be developed for Yupelri?
Yupelri is a small molecule drug, not a biologic. Biosimilars are intended for biologic medications, which are typically larger and more complex molecules. Therefore, the development pathway for generic versions of small molecule drugs like Yupelri differs from that of biosimilars for biologics.
What are the potential side effects of Yupelri?
Common side effects associated with Yupelri include upper respiratory tract infection, cough, and nasopharyngitis (symptoms of the common cold) [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How is Yupelri administered?
Yupelri is given as a once-daily inhalation using a standard jet nebulizer and mouthpiece or face mask [2]. It is a solution for nebulization that delivers the 175 mcg dose in 3 mL volume [1].
Who manufactures Yupelri?
The manufacturer of Yupelri is currently Sunovion Pharmaceuticals, Inc. [1].
What is the prescribed dosage and administration for Yupelri?
The recommended dose of Yupelri is 175 mcg inhaled once daily. It is supplied as a 3 mL solution for nebulization [1].
What are the alternatives to Yupelri for COPD treatment?
Treatment for COPD often involves a combination of therapies. Alternatives to LAMA medications like Yupelri may include other bronchodilators such as long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), or combination inhalers that include these drug classes [3]. The choice of treatment depends on the severity of COPD, individual patient response, and physician recommendation [3].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/drug-safety-communications-fda-cders-safety-program
[3] https://www.mayoclinic.org/diseases-conditions/copd/diagnosis-treatment/drc-20353671